Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome

References

• Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2012;5:199–207. doi:10.1177/1756283X11430859.
   Google Scholar
• Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15518–15531. doi:10.3748/wjg.v20.i42.15518.
   Google Scholar
• Mavrogiannaki AN, Migdalis IN. Nonalcoholic fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol. 2013;2013:450639. doi:10.1155/2013/450639.
   Google Scholar
• Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263–2273. doi:10.1001/jama.2015.5370.
   Google Scholar
• Caussy C, Soni M, Cui J, Bettencourt R, Schork N, Chen CH, Ikhwan MA, Bassirian S, Cepin S, Gonzalez MP, et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest. 2017;127:2697–2704. doi:10.1172/JCI93465.
   Google Scholar
• Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, Hu Y, Li J, Liu Y. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096. doi:10.1038/srep08096.
   Google Scholar
• Cui X, Ye L, Li J, Jin L, Wang W, Li S, Bao M, Wu S, Li L, Geng B, et al. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci Rep. 2018;8:635. doi:10.1038/s41598-017-18756-2.
   Google Scholar
• Kundu P, Blacher E, Elinav E, Pettersson S. Our gut microbiome: the evolving inner self. Cell. 2017;171:1481–1493. doi:10.1016/j.cell.2017.11.024.
   Google Scholar
• Lindheim L, Bashir M, Munzker J, Trummer C, Zachhuber V, Leber B, Horvath A, Pieber TR, Gorkiewicz G, Stadlbauer V, et al. Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): a pilot study. PLoS One. 2017;12:e0168390. doi:10.1371/journal.pone.0168390.
   Google Scholar
• Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13:193–204. doi:10.1080/17474124.2019.1569513.
   Google Scholar
• Hong M, Han DH, Hong J, Kim DJ, Suk KT. Are probiotics effective in targeting alcoholic liver diseases? Probiotics Antimicrob Proteins. 2018. doi:10.1007/s12602-018-9419-6.
   Google Scholar
• Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, Zhao X, Li N, Li S, Xue G, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 2019;30:675–88 e7. doi:10.1016/j.cmet.2019.08.018.
   Google Scholar
• Chen J, Thomsen M, Vitetta L. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. J Cell Biochem. 2019;120:2713–2720. doi:10.1002/jcb.27635.
   Google Scholar
• Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013;19:6911–6918. doi:10.3748/wjg.v19.i40.6911.
   Google Scholar
• Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 2018;56:855–867. doi:10.1007/s12275-018-8346-2.
   Google Scholar
• Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473–487. doi:10.2147/CEG.S27530.
   Google Scholar
• Cats A, Kuipers EJ, Bosschaert MA, Pot RG, Vandenbroucke-Grauls CM, Kusters JG. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther. 2003;17:429–435. doi:10.1046/j.1365-2036.2003.01452.x.
   Google Scholar
• Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, Bisson J-F, Rougeot C, Pichelin M, Cazaubiel M, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011;105:755–764. doi:10.1017/S0007114510004319.
   Google Scholar
• Pritchard GG, Coolbear T. The physiology and biochemistry of the proteolytic system in lactic acid bacteria. FEMS Microbiol Rev. 1993;12:179–206. doi:10.1111/j.1574-6976.1993.tb00018.x.
   Google Scholar
• Jauhiainen T, Ronnback M, Vapaatalo H, Wuolle K, Kautiainen H, Groop PH, Korpela R. Long-term intervention with Lactobacillus helveticus fermented milk reduces augmentation index in hypertensive subjects. Eur J Clin Nutr. 2010;64:424–431. doi:10.1038/ejcn.2010.3.
   Google Scholar
• Bahl MI, Bergstrom A, Licht TR. Freezing fecal samples prior to DNA extraction affects the Firmicutes to Bacteroidetes ratio determined by downstream quantitative PCR analysis. FEMS Microbiol Lett. 2012;329:193–197. doi:10.1111/j.1574-6968.2012.02523.x.
   Google Scholar
• Koliada A, Syzenko G, Moseiko V, Budovska L, Puchkov K, Perederiy V, Gavalko Y, Dorofeyev A, Romanenko M, Tkach S, et al. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol. 2017;17:120. doi:10.1186/s12866-017-1027-1.
   Google Scholar
• Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung Y-M, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57–63. doi:10.1038/nature09922.
   Google Scholar
• Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manneras-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23:850–858. doi:10.1038/nm.4345.
   Google Scholar
• Fourie NH, Wang D, Abey SK, Sherwin LB, Joseph PV, Rahim-Williams B, Ferguson EG, Henderson WA. The microbiome of the oral mucosa in irritable bowel syndrome. Gut Microbes. 2016;7:286–301. doi:10.1080/19490976.2016.1162363.
   Google Scholar
• Sung H, Kim SW, Hong M, Suk KT. Microbiota-based treatments in alcoholic liver disease. World J Gastroenterol. 2016;22:6673–6682. doi:10.3748/wjg.v22.i29.6673.
   Google Scholar
• Kim DH, Jeong D, Kang IB, Kim H, Song KY, Seo KH. Dual function of Lactobacillus kefiri DH5 in preventing high-fat-diet-induced obesity: direct reduction of cholesterol and upregulation of PPAR-alpha in adipose tissue. Mol Nutr Food Res. 2017:61. doi:10.1002/mnfr.201700252.
   Google Scholar
• Ji Y, Park S, Park H, Hwang E, Shin H, Pot B, Holzapfel WH. Modulation of active gut microbiota by lactobacillus rhamnosus GG in a diet induced obesity murine model. Front Microbiol. 2018;9:710. doi:10.3389/fmicb.2018.00710.
   Google Scholar
• Humphries C. Microbiome: detecting diversity. Nature. 2017;550:S12–S4. doi:10.1038/550S12a.
   Google Scholar
• Foster KR, Schluter J, Coyte KZ, Rakoff-Nahoum S. The evolution of the host microbiome as an ecosystem on a leash. Nature. 2017;548:43–51. doi:10.1038/nature23292.
   Google Scholar
• Koutnikova H, Genser B, Monteiro-Sepulveda M, Faurie JM, Rizkalla S, Schrezenmeir J, Clément K. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2019;9:e017995. doi:10.1136/bmjopen-2017-017995.
   Google Scholar
• Million M, Angelakis E, Paul M, Armougom F, Leibovici L, Raoult D. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog. 2012;53:100–108. doi:10.1016/j.micpath.2012.05.007.
   Google Scholar
• Damodharan K, Lee YS, Palaniyandi SA, Yang SH, Suh JW. Preliminary probiotic and technological characterization of Pediococcus pentosaceus strain KID7 and in vivo assessment of its cholesterol-lowering activity. Front Microbiol. 2015;6:768. doi:10.3389/fmicb.2015.00768.
   Google Scholar
• Chen Y, Li R, Chang Q, Dong Z, Yang H, Xu C. Lactobacillus bulgaricus or lactobacillus rhamnosus suppresses NF-kappaB signaling pathway and protects against AFB(1)-induced hepatitis: a novel potential preventive strategy for aflatoxicosis? Toxins (Basel). 2019;11:17. doi:10.3390/toxins11010017.
   Google Scholar
• Amin KA, Kamel HH, Eltawab MAA. Protective effect of Garcinia against renal oxidative stress and biomarkers induced by high fat and sucrose diet. Lipids Health Dis. 2011;10:6. doi:10.1186/1476-511X-10-6.
   Google Scholar
• Shavakhi A, Minakari M, Firouzian H, Assali R, Hekmatdoost A, Ferns G. Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: a double blind randomized clinical trial. Int J Prev Med. 2013;4:531–537.
   Google Scholar
• De Santis A, Famularo G, De Simone C. Probiotics for the hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol. 2000;95:323–324. doi:10.1111/j.1572-0241.2000.01726.x.
   Google Scholar
• Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37:343–350. doi:10.1053/jhep.2003.50048.
   Google Scholar
• Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007. doi:10.1002/14651858.CD005165.pub2.
   Google Scholar
• Nagata K, Suzuki H, Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci. 2007;32:453–468. doi:10.2131/jts.32.453.
   Google Scholar
• Mykhal’chyshyn HP, Bodnar PM, Kobyliak NM. Effect of probiotics on proinflammatory cytokines level in patients with type 2 diabetes and nonalcoholic fatty liver disease. Lik's Sprava. 01 Mar 2013;2:56–62.
   Google Scholar
• Okubo H, Sakoda H, Kushiyama A, Fujishiro M, Nakatsu Y, Fukushima T, Matsunaga Y, Kamata H, Asahara T, Yoshida Y, et al. Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am J Physiol Gastrointest Liver Physiol. 2013;305:G911–8. doi:10.1152/ajpgi.00225.2013.
   Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu Y-C, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. doi:10.1002/hep.20701.
   Google Scholar
• Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474. doi:10.1111/j.1572-0241.1999.01377.x.
   Google Scholar
• Yoshida N, Emoto T, Yamashita T, Watanabe H, Hayashi T, Tabata T, Hoshi N, Hatano N, Ozawa G, Sasaki N, et al. Bacteroides vulgatus and bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulation. 2018;138:2486–2498. doi:10.1161/CIRCULATIONAHA.118.033714.
   Google Scholar
• Anderson RC, Cookson AL, McNabb WC, Park Z, McCann MJ, Kelly WJ, Roy NC. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol. 2010;10:316. doi:10.1186/1471-2180-10-316.
   Google Scholar
• Yoon SH, Ha SM, Kwon S, Lim J, Kim Y, Seo H, Chun J. Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies. Int J Syst Evol Microbiol. 2017;67:1613–1617. doi:10.1099/ijsem.0.001755.
   Google Scholar
• Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26:2460–2461. doi:10.1093/bioinformatics/btq461.
   Google Scholar
• Park SJ, Kim JK, Kim -H-H, Yoon B-A, Ji DY, Lee C-W, Kim HJ, Kim KH, Shin HY, Park SJ, et al. Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants. Sci Rep. 2019;9:1077. doi:10.1038/s41598-018-37572-w.
   Google Scholar
• Ji DY, Park SH, Park SJ, Kim KH, Ku CR, Shin DY, Yoon JS, Lee DY, Lee EJ. Comparative assessment of Graves’ disease and main extrathyroidal manifestation, Graves’ ophthalmopathy, by non-targeted metabolite profiling of blood and orbital tissue. Sci Rep. 2018;8:9262. doi:10.1038/s41598-018-27600-0.
   Google Scholar
• Polyzos AA, Lee DY, Datta R, Hauser M, Budworth H, Holt A, Mihalik S, Goldschmidt P, Frankel K, Trego K, et al. Metabolic reprogramming in astrocytes distinguishes region-specific neuronal susceptibility in Huntington Mice. Cell Metab. 2019;29:1258–1273.e11. doi:10.1016/j.cmet.2019.03.004.
   Google Scholar
• Lee EM, Park SJ, Lee J-E, Lee BM, Shin BK, Kang DJ, Choi H-K, Kim Y-S, Lee DY. Highly geographical specificity of metabolomic traits among Korean domestic soybeans (Glycine max). Food Res Int. 2019;120:12–18. doi:10.1016/j.foodres.2019.02.021.
   Google Scholar
• Li B, Tang J, Yang Q, Li S, Cui X, Li Y, Chen Y, Xue W, Li X, Zhu F, et al. NOREVA: normalization and evaluation of MS-based metabolomics data. Nucleic Acids Res. 2017;45:W162–W70. doi:10.1093/nar/gkx449.
   Google Scholar